3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/147810 |
Resumo: | Summary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype. |
id |
RCAP_6aaa00f240766f711633e1505146cd6d |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/147810 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosineMiltefosine resistanceVisceral leishmaniasisCRISPR-Cas9;3’nucleotidase/nucleasePrognostic markerRM Therapeutics. PharmacologyQ ScienceQR MicrobiologyApplied Microbiology and BiotechnologyParasitologyGeneticsMolecular BiologySDG 3 - Good Health and Well-beingSummary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype.Instituto de Higiene e Medicina Tropical (IHMT)Individual Health Care (IHC)Global Health and Tropical Medicine (GHTM)Universidade NOVA de LisboaRUNCarniellie, JulianaDave, AnujaRomano, AudreyForrester, SarahFaria, PedroRenata, Monti-Rocha,Costa, CarlosDietze, RGraham, IanMottram, Jeremy C.2023-01-18T22:17:05Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147810eng2352-3964PURE: 50622397https://doi.org/10.1016/j.ebiom.2022.104378info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:29:03Zoai:run.unl.pt:10362/147810Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:53:05.379140Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
title |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
spellingShingle |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine Carniellie, Juliana Miltefosine resistance Visceral leishmaniasis CRISPR-Cas9; 3’nucleotidase/nuclease Prognostic marker RM Therapeutics. Pharmacology Q Science QR Microbiology Applied Microbiology and Biotechnology Parasitology Genetics Molecular Biology SDG 3 - Good Health and Well-being |
title_short |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
title_full |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
title_fullStr |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
title_full_unstemmed |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
title_sort |
3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosine |
author |
Carniellie, Juliana |
author_facet |
Carniellie, Juliana Dave, Anuja Romano, Audrey Forrester, Sarah Faria, Pedro Renata, Monti-Rocha, Costa, Carlos Dietze, R Graham, Ian Mottram, Jeremy C. |
author_role |
author |
author2 |
Dave, Anuja Romano, Audrey Forrester, Sarah Faria, Pedro Renata, Monti-Rocha, Costa, Carlos Dietze, R Graham, Ian Mottram, Jeremy C. |
author2_role |
author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Instituto de Higiene e Medicina Tropical (IHMT) Individual Health Care (IHC) Global Health and Tropical Medicine (GHTM) Universidade NOVA de Lisboa RUN |
dc.contributor.author.fl_str_mv |
Carniellie, Juliana Dave, Anuja Romano, Audrey Forrester, Sarah Faria, Pedro Renata, Monti-Rocha, Costa, Carlos Dietze, R Graham, Ian Mottram, Jeremy C. |
dc.subject.por.fl_str_mv |
Miltefosine resistance Visceral leishmaniasis CRISPR-Cas9; 3’nucleotidase/nuclease Prognostic marker RM Therapeutics. Pharmacology Q Science QR Microbiology Applied Microbiology and Biotechnology Parasitology Genetics Molecular Biology SDG 3 - Good Health and Well-being |
topic |
Miltefosine resistance Visceral leishmaniasis CRISPR-Cas9; 3’nucleotidase/nuclease Prognostic marker RM Therapeutics. Pharmacology Q Science QR Microbiology Applied Microbiology and Biotechnology Parasitology Genetics Molecular Biology SDG 3 - Good Health and Well-being |
description |
Summary Background Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum. The MSL comprises four genes, 3′ -nucleotidase/nucleases (NUC1 and NUC2); helicase-like protein (HLP); and 3,2-trans-enoyl-CoA isomerase (TEI). Methods In this study CRISPR-Cas9 was used to either epitope tag or delete NUC1, NUC2, HLP and TEI, to investigate their role in miltefosine resistance mechanisms. Additionally, miltefosine transporter genes and miltefosine-mediated reactive oxygen species homeostasis were assessed in 26 L. infantum clinical isolates. A comparative lipidomic analysis was also performed to investigate the molecular basis of miltefosine resistance. Findings Deletion of both NUC1, NUC2 from the MSL was associated with a significant decrease in miltefosine susceptibility, which was restored after re-expression. Metabolomic analysis of parasites lacking the MSL or NUC1 and NUC2 identified an increase in the parasite lipid content, including ergosterol; these lipids may contribute to miltefosine resistance by binding the drug in the membrane. Parasites lacking the MSL are more resistant to lipid metabolism perturbation caused by miltefosine and NUC1 and NUC2 are involved in this pathway. Additionally, L. infantum parasites lacking the MSL isolated from patients who relapsed after miltefosine treatment were found to modulate nitric oxide accumulation in host macrophages. Interpretation Altogether, these data indicate that multifactorial mechanisms are involved in natural resistance to miltefosine in L. infantum and that the absence of the 3’nucleotidase/nuclease genes NUC1 and NUC2 contributes to the phenotype. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022 2022-01-01T00:00:00Z 2023-01-18T22:17:05Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/147810 |
url |
http://hdl.handle.net/10362/147810 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2352-3964 PURE: 50622397 https://doi.org/10.1016/j.ebiom.2022.104378 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138122306420736 |